Preclinical development of an oral anti-Wolbachiamacrolide drug for the treatment of lymphatic filariasis and onchocerciasis

MLA

Taylor, Mark J., et al. “Preclinical Development of an Oral Anti-Wolbachiamacrolide Drug for the Treatment of Lymphatic Filariasis and Onchocerciasis.” Science Translational Medicine, vol. 11, no. 483, Mar. 2019. EBSCOhost, https://doi.org/10.1126/scitranslmed.aau2086.

APA

Taylor, M. J., von Geldern, T. W., Ford, L., Hübner, M. P., Marsh, K., Johnston, K. L., Sjoberg, H. T., Specht, S., Pionnier, N., Tyrer, H. E., Clare, R. H., Cook, D. A. N., Murphy, E., Steven, A., Archer, J., Bloemker, D., Lenz, F., Koschel, M., Ehrens, A., … Ward, S. A. (2019). Preclinical development of an oral anti-Wolbachiamacrolide drug for the treatment of lymphatic filariasis and onchocerciasis. Science Translational Medicine, 11(483). https://doi.org/10.1126/scitranslmed.aau2086

Chicago

Taylor, Mark J., Thomas W. von Geldern, Louise Ford, Marc P. Hübner, Kennan Marsh, Kelly L. Johnston, Hanna T. Sjoberg, et al. 2019. “Preclinical Development of an Oral Anti-Wolbachiamacrolide Drug for the Treatment of Lymphatic Filariasis and Onchocerciasis.” Science Translational Medicine 11 (483). doi:10.1126/scitranslmed.aau2086.